CDCA3

Summary

CDCA3 (cell division cycle associated 3, HGNC:14624) is a protein-coding gene on chromosome 12p13.31, encoding Cell division cycle-associated protein 3 (Q99618). F-box-like protein which is required for entry into mitosis. It is a selective cancer dependency (DepMap: 20.0% of cell lines).

Predicted to be involved in cell division and protein ubiquitination. Located in adherens junction.

Source: NCBI Gene 83461 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 138 total — 1 pathogenic
• Cancer dependency (DepMap): dependent in 20.0% of screened cell lines
• MANE Select transcript: NM_031299

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14624
Approved symbol	CDCA3
Name	cell division cycle associated 3
Location	12p13.31
Locus type	gene with protein product
Status	Approved
Aliases	TOME-1, GRCC8
Ensembl gene	ENSG00000111665
Ensembl biotype	protein_coding
OMIM	607749
Entrez	83461

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 9 protein_coding, 5 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000229265, ENST00000422785, ENST00000446553, ENST00000535406, ENST00000535871, ENST00000536241, ENST00000538862, ENST00000540683, ENST00000544610, ENST00000545368, ENST00000603043, ENST00000604599, ENST00000927229, ENST00000927230, ENST00000927231, ENST00000927232

RefSeq mRNA: 5 — MANE Select: NM_031299 NM_001297602, NM_001297603, NM_001297604, NM_001331019, NM_031299

CCDS: CCDS73428, CCDS76512, CCDS76513, CCDS8565

Canonical transcript exons

ENST00000538862 — 6 exons

Exon	Start	End
ENSE00000716130	6849323	6849429
ENSE00002274400	6851222	6851286
ENSE00003501011	6850467	6850596
ENSE00003536492	6848828	6849198
ENSE00003565778	6849565	6849858
ENSE00003620640	6850833	6851009

Expression profiles

Bgee: expression breadth ubiquitous, 199 present calls, max score 96.49.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.1008 / max 182.9738, expressed in 1394 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
129206	21.1008	1394

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	96.49	gold quality
oocyte	CL:0000023	96.03	gold quality
secondary oocyte	CL:0000655	94.41	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	92.87	gold quality
left testis	UBERON:0004533	91.40	gold quality
right testis	UBERON:0004534	91.37	gold quality
ganglionic eminence	UBERON:0004023	90.46	gold quality
embryo	UBERON:0000922	90.04	gold quality
duodenum	UBERON:0002114	89.42	gold quality
testis	UBERON:0000473	89.39	gold quality
jejunal mucosa	UBERON:0000399	88.09	gold quality
mucosa of transverse colon	UBERON:0004991	87.61	gold quality
ileal mucosa	UBERON:0000331	86.06	gold quality
lower esophagus mucosa	UBERON:0035834	85.81	gold quality
trabecular bone tissue	UBERON:0002483	84.64	gold quality
bone marrow	UBERON:0002371	83.87	gold quality
small intestine Peyer’s patch	UBERON:0003454	83.41	gold quality
small intestine	UBERON:0002108	83.24	gold quality
esophagus mucosa	UBERON:0002469	82.87	gold quality
right hemisphere of cerebellum	UBERON:0014890	82.77	gold quality
stromal cell of endometrium	CL:0002255	82.02	gold quality
cerebellar hemisphere	UBERON:0002245	81.95	gold quality
rectum	UBERON:0001052	81.79	gold quality
cerebellar cortex	UBERON:0002129	81.75	gold quality
bone marrow cell	CL:0002092	81.46	gold quality
adult organism	UBERON:0007023	81.04	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.71	gold quality
vermiform appendix	UBERON:0001154	80.15	gold quality
lymph node	UBERON:0000029	79.90	gold quality
esophagus squamous epithelium	UBERON:0006920	79.76	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-13	yes	23.34
E-MTAB-6678	yes	7.61
E-ANND-3	yes	5.00
E-MTAB-6142	no	522.20
E-MTAB-7249	no	64.37

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOXC1, HOXB3

miRNA regulators (miRDB)

43 targeting CDCA3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488
HSA-MIR-548W	99.94	71.24	3488
HSA-MIR-548Y	99.94	71.28	3514
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 20.0% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 24)

• a repressor element (cell-cycle-dependent element/cell cycle gene homology region) in the vicinity of the transcription start site, and mutations within this element diminished the cell-cycle-dependent transcriptional regulation of Tome-1 (PMID:15733861)
• overexpression of CDCA3 occurs frequently during oral carcinogenesis. (PMID:22839099)
• HoxB3 promote prostate cancer progression by upregulating CDCA3 expression. (PMID:23219899)
• High CDCA3 expression is associated with neoplasms. (PMID:25236463)
• OY-TES-1 downregulation in liver cancer cells promotes cell proliferation by upregulating CCND2 and CDCA3. (PMID:25673160)
• Data indicate a miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry which contributes to leukemogenesis and suggest a therapeutic strategy of restoring miR-375 expression in Acute myeloid leukemia (AML). (PMID:29439669)
• these results define a tumor-supportive role for CDCA3. (PMID:29627567)
• Study demonstrated that CDCA3 may target p21 to promote colorectal cancer (CRC) cell proliferation and tumorigenesis, at least partially in an E2F1-mediated manner, and that CDCA3 may serve as a potential prognostic and therapeutic target of CRC. (PMID:30226575)
• Study results demonstrated that CDCA3 expression was increased in human gastric cancer (GC) tissues compared with those in adjacent nontumor tissues CDCA3 expression was closely associated with features of GC and patients with unfavorable overall survival times. CDCA3 overexpression resulted in the stimulation of cell growth and colony formation in vitro and xenograft tumors in vivo. (PMID:30816466)
• DNA hypomethylation promotes invasion and metastasis of gastric cancer cells by regulating the binding of SP1 to the CDCA3 promoter. (PMID:31211445)
• miR-145-5p suppresses proliferation, metastasis and EMT of colorectal cancer by targeting CDCA3. (PMID:32107086)
• Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma. (PMID:32641718)
• Downregulation of CDCA3 expression inhibits tumor formation in pancreatic cancer. (PMID:32701354)
• Circ_0001421 facilitates glycolysis and lung cancer development by regulating miR-4677-3p/CDCA3. (PMID:33109222)
• CDCA3 Is a Novel Prognostic Biomarker Associated with Immune Infiltration in Hepatocellular Carcinoma. (PMID:33604380)
• Circular RNA hsa_circ_101555 promotes hepatocellular carcinoma cell proliferation and migration by sponging miR-145-5p and regulating CDCA3 expression. (PMID:33824281)
• Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy. (PMID:34050247)
• Prognostic value of CDCA3 in kidney renal papillary cell carcinoma. (PMID:34905505)
• Suppression of CDCA3 inhibits prostate cancer progression via NFkappaB/cyclin D1 signaling inactivation and p21 accumulation. (PMID:34970697)
• LncCDCA3L inhibits cell proliferation via a novel RNA structure-based crosstalk with CDCA3 in hepatocellular carcinoma. (PMID:35230745)
• MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3. (PMID:36071275)
• CDCA3 exhibits a role in promoting the progression of ovarian cancer. (PMID:36081320)
• MiRNA-144-5p down-modulates CDCA3 to regulate proliferation and apoptosis of lung adenocarcinoma cells. (PMID:36087462)
• Identification of circ_0038632 as a Promoter of Breast Cancer through miR-520a-3p-Dependent Modulation of CDCA3. (PMID:37625824)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	cdca3	ENSDARG00000070656
mus_musculus	Cdca3	ENSMUSG00000023505
rattus_norvegicus	Cdca3	ENSRNOG00000015529
drosophila_melanogaster	msb1l	FBGN0027949

Protein

Protein identifiers

Cell division cycle-associated protein 3 — Q99618 (reviewed: Q99618)

Alternative names: Gene-rich cluster protein C8, Trigger of mitotic entry protein 1

All UniProt accessions (4): Q99618, F5GX58, F8WDL1, J3KMY0

UniProt curated annotations — full annotation on UniProt →

Function. F-box-like protein which is required for entry into mitosis. Acts by participating in E3 ligase complexes that mediate the ubiquitination and degradation of WEE1 kinase at G2/M phase.

Subunit / interactions. Interacts with SKP1. Part of a SCF (SKP1-cullin-F-box) protein ligase complex.

Subcellular location. Cytoplasm. Cytosol.

Post-translational modifications. Ubiquitinated and degraded by the APC/C-Cdh1 complex.

Domain organisation. The KEN box is required for the association with the APC/C-Cdh1 complex.

Pathway. Protein modification; protein ubiquitination.

RefSeq proteins (5): NP_001284531, NP_001284532, NP_001284533, NP_001317948, NP_112589* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR038832	CDCA3	Family

UniProt features (25 total): modified residue 13, compositionally biased region 7, region of interest 3, chain 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q99618-F1	59.01	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (13): 29, 31, 37, 44, 64, 68, 76, 87, 94, 199, 202, 209, 212

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 275 (showing top): HORIUCHI_WTAP_TARGETS_DN, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GNF2_CENPF, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP, DITTMER_PTHLH_TARGETS_UP, IVANOVA_HEMATOPOIESIS_MATURE_CELL, KONG_E2F3_TARGETS, CAGCTG_AP4_Q5, SHEPARD_BMYB_MORPHOLINO_DN, GOLDRATH_ANTIGEN_RESPONSE, LI_WILMS_TUMOR_ANAPLASTIC_UP, GNF2_HMMR, MCAATNNNNNGCG_UNKNOWN, FISCHER_G2_M_CELL_CYCLE

GO Biological Process (2): protein ubiquitination (GO:0016567), cell division (GO:0051301)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): cytosol (GO:0005829), adherens junction (GO:0005912), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
protein modification by small protein conjugation	1
cellular process	1
binding	1
cytoplasm	1
cell-cell junction	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1436 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDCA3	WEE1	P30291	845
CDCA3	CDK1	P06493	778
CDCA3	CDCA2	Q69YH5	721
CDCA3	SKP1	P34991	667
CDCA3	CDCA8	Q53HL2	665
CDCA3	CDC20	Q12834	644
CDCA3	NUSAP1	Q9BXS6	622
CDCA3	KIF4A	O95239	617
CDCA3	AURKB	Q96GD4	612
CDCA3	CEP55	Q53EZ4	588
CDCA3	CDCA5	Q96FF9	580
CDCA3	NUF2	Q9BZD4	570
CDCA3	TOP2A	P11388	564
CDCA3	NEK2	P51955	554
CDCA3	CTDSP1	Q9GZU7	550

IntAct

140 interactions, top by confidence:

A	B	Type	Score
CTDSP1	CDCA3	psi-mi:“MI:0915”(physical association)	0.940
CDCA3	CTDSP1	psi-mi:“MI:0915”(physical association)	0.940
CTDSP1	CDCA3	psi-mi:“MI:0914”(association)	0.940
CTDSP2	CDCA3	psi-mi:“MI:0915”(physical association)	0.900
CDCA3	CTDSP2	psi-mi:“MI:0915”(physical association)	0.900
TRAF2	CDCA3	psi-mi:“MI:0915”(physical association)	0.780
CDCA3	TRAF2	psi-mi:“MI:0915”(physical association)	0.780
TRAF1	CDCA3	psi-mi:“MI:0915”(physical association)	0.720
CDCA3	TRAF1	psi-mi:“MI:0915”(physical association)	0.720
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
CDCA3	CTDSPL	psi-mi:“MI:0914”(association)	0.670
CTDSP1	CTDSPL	psi-mi:“MI:0914”(association)	0.640

BioGRID (260): SKP1 (Co-fractionation), CUL1 (Reconstituted Complex), CDCA3 (Two-hybrid), CDCA3 (Two-hybrid), CDCA3 (Two-hybrid), CDCA3 (Two-hybrid), CDCA3 (Affinity Capture-MS), CDCA3 (Affinity Capture-MS), NMT1 (Affinity Capture-MS), FZR1 (Affinity Capture-MS), CTDSPL (Affinity Capture-MS), ATP6V1C1 (Affinity Capture-MS), LAMTOR4 (Affinity Capture-MS), CTDNEP1 (Affinity Capture-MS), CDCA3 (Two-hybrid)

ESM2 similar proteins: A0A1B0GTI1, A2BIL8, A5PKK9, C5DY61, E2QSX5, E7F555, O35147, O43151, P11805, P19416, P24940, P27579, Q06616, Q17QE3, Q1LZE2, Q1RMQ5, Q1T763, Q28CW2, Q2HR82, Q2TBN9, Q3B8E9, Q3ZBS1, Q567C6, Q5RDK8, Q62417, Q68FW2, Q6AY26, Q6DFB0, Q6P6I6, Q6PKN7, Q80U49, Q86YL5, Q8C3W1, Q8QVM1, Q8VEB3, Q8VI59, Q96FT9, Q96GV9, Q96GY3, Q99618

Diamond homologs: P0C2X8, Q68FW2, Q99618, Q99M54

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
CDC14B	up-regulates	CDCA3	dephosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 133 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	5	29.8×	3e-05
Downstream signal transduction	6	26.2×	8e-06
DAP12 signaling	5	21.2×	1e-04
NCAM signaling for neurite out-growth	5	15.6×	3e-04
EPH-ephrin mediated repulsion of cells	6	15.2×	1e-04
Constitutive Signaling by Aberrant PI3K in Cancer	10	14.6×	5e-07
Signaling by SCF-KIT	5	14.3×	5e-04
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	11	12.2×	5e-07

GO biological processes:

GO term	Partners	Fold	FDR
peptidyl-tyrosine phosphorylation	9	34.8×	2e-09
ephrin receptor signaling pathway	7	22.1×	4e-06
cell surface receptor protein tyrosine kinase signaling pathway	12	19.1×	1e-09
protein autophosphorylation	11	14.7×	6e-08
positive regulation of neuron projection development	11	13.8×	9e-08
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	15	10.8×	3e-09
cellular response to retinoic acid	5	10.7×	5e-03
neuron apoptotic process	6	10.2×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

138 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	92
Likely benign	24
Benign	12

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
242984	NM_002075.4(GNB3):c.1017G>A (p.Trp339Ter)	Pathogenic

SpliceAI

1068 predictions. Top by Δscore:

Variant	Effect	Δscore
12:6845575:C:A	acceptor_gain	1.0000
12:6845577:T:TA	acceptor_gain	1.0000
12:6845581:CTCA:C	acceptor_loss	1.0000
12:6845582:TCA:T	acceptor_loss	1.0000
12:6845583:CAG:C	acceptor_loss	1.0000
12:6845584:A:AG	acceptor_gain	1.0000
12:6845584:AGTT:A	acceptor_loss	1.0000
12:6845585:G:GT	acceptor_gain	1.0000
12:6845585:GT:G	acceptor_gain	1.0000
12:6845585:GTT:G	acceptor_gain	1.0000
12:6845585:GTTC:G	acceptor_gain	1.0000
12:6845585:GTTCT:G	acceptor_gain	1.0000
12:6845786:G:GT	donor_gain	1.0000
12:6845795:GCGT:G	donor_gain	1.0000
12:6849561:GTACC:G	donor_loss	1.0000
12:6849562:TACCT:T	donor_loss	1.0000
12:6849563:A:G	donor_loss	1.0000
12:6849564:C:A	donor_loss	1.0000
12:6845572:ACCC:A	acceptor_gain	0.9900
12:6845799:GTGG:G	donor_gain	0.9900
12:6845801:GG:G	donor_gain	0.9900
12:6845802:GG:G	donor_gain	0.9900
12:6849315:T:TA	donor_gain	0.9900
12:6849565:C:A	donor_loss	0.9900
12:6849859:C:CC	acceptor_gain	0.9900
12:6850461:GCTTA:G	donor_loss	0.9900
12:6850462:CTTAC:C	donor_loss	0.9900
12:6850464:TACCT:T	donor_loss	0.9900
12:6850466:C:CT	donor_loss	0.9900
12:6850595:ACCT:A	acceptor_loss	0.9900

AlphaMissense

1711 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:6850837:A:T	I39N	0.991
12:6850837:A:G	I39T	0.990
12:6850847:G:T	R36S	0.990
12:6850852:A:G	I34T	0.990
12:6850837:A:C	I39S	0.985
12:6850871:G:T	R28S	0.985
12:6850518:G:T	R67S	0.984
12:6850860:A:C	S31R	0.983
12:6850860:A:T	S31R	0.983
12:6850862:T:G	S31R	0.983
12:6850876:T:C	D26G	0.980
12:6850852:A:C	I34S	0.978
12:6850877:C:G	D26H	0.974
12:6850868:A:G	S29P	0.972
12:6850840:G:T	P38H	0.968
12:6850875:G:C	D26E	0.966
12:6850875:G:T	D26E	0.966
12:6850876:T:A	D26V	0.964
12:6850876:T:G	D26A	0.963
12:6850515:A:G	S68P	0.961
12:6850511:G:T	P69H	0.957
12:6850846:C:G	R36P	0.957
12:6850935:G:C	S6R	0.957
12:6850935:G:T	S6R	0.957
12:6850937:T:G	S6R	0.957
12:6850499:A:C	I73S	0.956
12:6850864:G:T	P30H	0.956
12:6850499:A:T	I73N	0.955
12:6850870:C:G	R28P	0.954
12:6850949:C:G	G2R	0.954

dbSNP variants (sampled 300 via entrez): RS1001237782 (12:6847183 C>A,T), RS1003545766 (12:6848991 A>G), RS1006054296 (12:6851107 C>G), RS1006086774 (12:6850866 T>C), RS1006284085 (12:6844703 G>A,C), RS1007058310 (12:6846461 A>G), RS1007441156 (12:6845330 G>A), RS1008085951 (12:6847511 T>C), RS1008104507 (12:6848181 C>A,T), RS1008571341 (12:6852714 T>G), RS1009568695 (12:6848541 T>C), RS1009901914 (12:6847145 G>A,C), RS1010132418 (12:6853189 C>T), RS1010523511 (12:6850100 A>G), RS1010579543 (12:6852797 C>A)

Disease associations

OMIM: gene MIM:607749 | disease phenotypes: MIM:617024, MIM:145500

GenCC curated gene-disease

Mondo (2): congenital stationary night blindness 1H (MONDO:0014872), essential hypertension, genetic (MONDO:0007781)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

4 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs5442	CDCA3, GNB3, USP5		0.00	0
rs5443	CDCA3, GNB3, USP5	3	5.00	15	bumetanide;furosemide;torasemide;methadone;atenolol;antidepressants;HMG-CoA reductase inhibitors;sumatriptan;olanzapine;sildenafil;nortriptyline;Beta Blocking Agents
rs5445	CDCA3, GNB3		0.00	0
rs2301339	CDCA3, GNB3, USP5	3	9.25	1	atenolol

CTD chemical–gene interactions

85 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects methylation, decreases expression, increases expression	4
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	3
Cyclosporine	decreases expression	3
bisphenol A	affects expression, decreases expression	2
cobaltous chloride	decreases expression	2
perfluorooctanoic acid	decreases expression	2
(+)-JQ1 compound	decreases expression	2
Air Pollutants	decreases expression, increases abundance	2
Benzo(a)pyrene	decreases expression	2
Cisplatin	increases reaction, affects expression, decreases expression	2
Coumestrol	affects cotreatment, increases expression, affects reaction	2
Tretinoin	decreases expression	2
Aflatoxin B1	decreases expression, increases methylation	2
Particulate Matter	decreases expression, increases abundance	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
fluorene-9-bisphenol	increases expression	1
methyleugenol	decreases expression	1
propionaldehyde	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
zinc chromate	decreases expression, increases abundance	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
coumarin	decreases phosphorylation	1
cupric oxide	decreases expression	1
diallyl trisulfide	decreases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
phenethyl isothiocyanate	decreases expression	1
chromium hexavalent ion	decreases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.